Semafore Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation for SF1126 in the Treatment of Chronic Lymphocytic Leukemia
Published: Nov 09, 2010
INDIANAPOLIS--(BUSINESS WIRE)--Semafore Pharmaceuticals announced today that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the Company’s SF1126 product candidate for the treatment of B-cell chronic lymphocytic leukemia (CLL). In April 2010, the Company initiated an expansion of its ongoing Phase I clinical study into this disease setting. SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR).